Although no definitive conclusion was demonstrated for the a priori defined end points of superiority (OR >1) or futility (OR <1.2), our results have clinical utility in that they do not support the routine use of a P2Y12 inhibitor in critically ill patients hospitalized for COVID-19. This evidence concerns the gene P2RY12 and COVID-19.